Cammack was head of the Virology Department at Welwyn Discovery Research for the past four years. Before joining Roche, he was with Glaxo for six years.
At Roche Bioscience, Cammack reports to Robert Booth, senior vice president and head, Inflammatory and Viral Diseases Unit, Palo Alto.
Cammack obtained a B.Sc. in Microbiology from the University of Leeds, U.K., and an M.Sc. in Virology from The University of Reading. He completed his Ph.D. on yellow fever virus at the University of London's School of Hygiene & Tropical Medicine
The Roche Bioscience pharmaceutical operations in Palo Alto is focused on the discovery and early clinical development of innovative new medicines to treat diseases including arthritis, asthma and other respiratory diseases; anxiety, depression, schizophrenia and other neuropsychiatric diseases; genitourinary diseases, osteoporosis, HIV/AIDS, and hepatitis C.
Located in the Stanford Research Park, Roche employs approximately 1,100 men and women in Palo Alto as part of the Roche Group. Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's innovative services address the prevention, diagnosis and treatment of diseases, thus enhancing people's well-being and quality of life.
Palo Alto, Calif., October 15, 2001 -- Nick Cammack, Ph.D., has been appointed head of viral diseases research at Roche Bioscience in Palo Alto, Calif. He is responsible for the research and discovery of new medicines to treat HIV/AIDS and hepatitis C virus, research which is being transferred to Palo Alto from Roche's facility in Welwyn, U.K.